How much does Neuraxpharm UK Limited make?

Neuraxpharm UK Limited reported revenue of £26m and a loss of £850k in the year to 31 Dec 2025, according to its accounts filed at Companies House.

How many employees does Neuraxpharm UK Limited have?

Neuraxpharm UK Limited reported an average of 28 employees in the year to 31 Dec 2025.

Is Neuraxpharm UK Limited profitable?

No — Neuraxpharm UK Limited reported a loss of £850k in the year to 31 Dec 2025.

Company No. 10918621 · Incorporated 16 Aug 2017

Neuraxpharm UK Limited

Registered name: NEURAXPHARM UK LIMITED

Part of Permira VII Investment Platform Limited group

Neuraxpharm UK Limited made £26m revenue and a £850k loss in the year to 31 Dec 2025.

Neuraxpharm UK Limited’s revenue grew 39% to £26m in the year to 31 Dec 2025, with a loss of £850k and 28 employees. The company is classified under “wholesale of pharmaceutical goods” and is based in Cardiff; we hold 4 years of its filed accounts.

Full P&L filedSection G · Wholesale and retail trade; repair of motor vehiclesSIC 46460Wholesale of pharmaceutical goods

Status: Active
Location: Cardiff, Wales
Age: 9 yrs · since 2017
Type: Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.

Latest accounts · year to 31 Dec 2025

Key figures

Capital-lightCash flow filed

Revenue

£26m

Growth ▲38.9%

Profit

−£850k

Growth —

Profit margin

−3.3%

Gross 27.6%

Employees

Change ▲86.7%

Profit / employee

−£30.4k

Revenue/employee £929k

Profitable streak

0yrs

Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

4 filed years

Financial history

Multi-year financials, oldest to newest
Year to	31 Dec 2022	31 Dec 2023	31 Dec 2024	31 Dec 2025
Disclosure	Full P&L	Full P&L	Full P&L	Full P&L
Profit & loss
Revenue (turnover)	£14.5m	£19.9m	£18.7m	£26m
Cost of sales	£11.3m	£16.4m	£15.5m	£18.8m
Gross profit	£3.2m	£3.5m	£3.2m	£7.2m
Operating profit	£229k	£619k	−£912k	−£950k
Profit before tax	£128k	£387k	−£1.2m	−£1.1m
Profit after tax	£82k	£304k	−£871k	−£850k
Profit (best available)	£82k	£304k	−£871k	−£850k
Staff costs	£720k	£808k	£1.6m	£3.3m
Employees (average)	7	9	15	28
Ratios
Profit margin	0.6%	1.5%	−4.7%	−3.3%
Gross margin	22%	17.7%	17.3%	27.6%
Revenue per employee	£2.1m	£2.2m	£1.2m	£929k
Profit per employee	£11.7k	£33.8k	−£58.1k	−£30.4k
Cash conversion	−921.8%	516.6%	—	—
Growth (year on year)
Revenue growth	—	▲37.4%	▼6%	▲38.9%
Profit growth	—	▲271.2%	▼386.3%	—
Headcount growth	—	▲28.6%	▲66.7%	▲86.7%
Balance sheet — indirect signals, not revenue
Cash at bank	£238k	£821k	£281k	£5.1m
Net assets	£383k	£687k	−£184k	−£1m
Fixed assets	£600k	£401k	£237k	£404k
Current assets	£7.2m	£12.4m	£13.2m	£23.6m
Debtors	£3.5m	£5.1m	£4.4m	£8.7m
Deferred income	£312k	£950k	£1.3m	£2.1m
Cash from operations	−£2.1m	£3.2m	£1.6m	−£2.7m
Source	FullAccounts · bulk data Sep 2024	FullAccounts · bulk data Sep 2024	FullAccounts · bulk data Sep 2025	FullAccounts · bulk data May 2026

Derived from the latest filing

How the business works

Profit margin: −3.3%; Profit ÷ revenue.
Gross margin: 27.6%; Gross profit ÷ revenue. High for software and services.
Revenue per employee: £929k; Revenue ÷ average employees.
Profit per employee: −£30.4k; Profit ÷ average employees.
Cash conversion: —; Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue: 1.6%; Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue: 8.3%; Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue: 33.4%; Money owed by customers. Low = customers pay quickly.

Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets: —; Now −£1m
Cash at bank: ▲1711%; Now £5.1m
Headcount: ▲87%; Now 28
Deferred income: ▲70%; Now £2.1m
Fixed assets: ▲71%; Now £404k

Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.

Corporate ownership

Group structure

Ownership chain

Permira VII Investment Platform Limitedultimate parent75–100%
Neuraxpharm UK Limitedthis company

Bands show the share of ownership each company holds in the one below it.

Sister companies (5)

Sevenplatform II LimitedFigures not disclosed
Sevenplatform III LimitedFigures not disclosed
Sevenplatform IX LimitedFigures not disclosed
Sevenplatform VI LimitedFigures not disclosed
Sevenplatform VII LimitedFigures not disclosed

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Companies House profile Filing history & original accounts

Latest figures from FullAccounts for the year to 31 Dec 2025 (profit −£850k), from the Companies House accounts bulk data published May 2026. Spotted an error? Request a correction.

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.